This inventor holds 11 USPTO granted patents, plus 2 CIPO patents and 11 EPO patents. Top assignees: Idorsia Pharmaceuticals Ltd, Actelion Pharmaceuticals Ltd. Active years: 2015-2024.
Company Filing History:
Years Active: 2015-2024
Title: The Innovative Contributions of Davide Pozzi
Introduction
Davide Pozzi is a notable inventor based in Allschwil, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that modulate prostaglandin receptors. With a total of 11 patents to his name, Pozzi's work has the potential to impact cancer treatment and other medical applications.
Latest Patents
Among his latest patents, Pozzi has developed N-substituted indole derivatives as PGE2 receptor modulators. This invention relates to derivatives of a specific formula, which are described in detail in the patent documentation. These compounds are intended for use as pharmaceuticals, particularly in modulating the prostaglandin 2 receptors EP2 and/or EP4. Another significant patent involves pyrimidine derivatives as PGE2 receptor modulators, which are aimed at treating cancer by reactivating the immune system in tumors. Additionally, he has introduced novel benzofurane and benzothiophene derivatives, further expanding the scope of his pharmaceutical innovations.
Career Highlights
Davide Pozzi has worked with prominent companies in the pharmaceutical industry, including Idorsia Pharmaceuticals Ltd and Actelion Pharmaceuticals Ltd. His experience in these organizations has allowed him to refine his expertise in drug development and innovation.
Collaborations
Throughout his career, Pozzi has collaborated with esteemed colleagues such